Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL
Jia Wang, Rui Cui, Yao Qi, Juan Mu, Xin Li, Qing Li, Qi Deng
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCAR-T cell therapy research · Chronic Lymphocytic Leukemia Research · Cutaneous lymphoproliferative disorders research
In the Abstract, two typographical errors were identified. In the last sentence of the Patients and Methods section, the original version incorrectly stated: “These 33 patients were stratified into two groups based on the duration of BTKi exposure: ≥x months versus <2 months.” In the first sentence of the Results section, it incorrectly stated: “The R/R DLBCL patients receiving BTKi for ≥o months demonstrated a higher overall response rate than the patients receiving BTKi for <2 month.”.
The corrected Abstract reads: “These 33 patients were stratified into two groups based on the duration of BTKi exposure: ≥2 months versus <2 months,” and “The R/R DLBCL patients receiving BTKi for ≥2 months demonstrated a higher overall response rate than the patients receiving BTKi for <2 months.”
The original version of this article has been updated.